WP_Query Object
(
[query] => Array
(
[post_type] => post
[posts_per_page] => 3
[post_status] => publish
[orderby] => rand
)
[query_vars] => Array
(
[post_type] => post
[posts_per_page] => 3
[post_status] => publish
[orderby] => rand
[error] =>
[m] =>
[p] => 0
[post_parent] =>
[subpost] =>
[subpost_id] =>
[attachment] =>
[attachment_id] => 0
[name] =>
[pagename] =>
[page_id] => 0
[second] =>
[minute] =>
[hour] =>
[day] => 0
[monthnum] => 0
[year] => 0
[w] => 0
[category_name] =>
[tag] =>
[cat] =>
[tag_id] =>
[author] =>
[author_name] =>
[feed] =>
[tb] =>
[paged] => 0
[meta_key] =>
[meta_value] =>
[preview] =>
[s] =>
[sentence] =>
[title] =>
[fields] => all
[menu_order] =>
[embed] =>
[category__in] => Array
(
)
[category__not_in] => Array
(
)
[category__and] => Array
(
)
[post__in] => Array
(
)
[post__not_in] => Array
(
)
[post_name__in] => Array
(
)
[tag__in] => Array
(
)
[tag__not_in] => Array
(
)
[tag__and] => Array
(
)
[tag_slug__in] => Array
(
)
[tag_slug__and] => Array
(
)
[post_parent__in] => Array
(
)
[post_parent__not_in] => Array
(
)
[author__in] => Array
(
)
[author__not_in] => Array
(
)
[search_columns] => Array
(
)
[ignore_sticky_posts] =>
[suppress_filters] =>
[cache_results] => 1
[update_post_term_cache] => 1
[update_menu_item_cache] =>
[lazy_load_term_meta] => 1
[update_post_meta_cache] => 1
[nopaging] =>
[comments_per_page] => 50
[no_found_rows] =>
[order] =>
)
[tax_query] => WP_Tax_Query Object
(
[queries] => Array
(
)
[relation] => AND
[table_aliases:protected] => Array
(
)
[queried_terms] => Array
(
)
[primary_table] => wp_posts
[primary_id_column] => ID
)
[meta_query] => WP_Meta_Query Object
(
[queries] => Array
(
)
[relation] =>
[meta_table] =>
[meta_id_column] =>
[primary_table] =>
[primary_id_column] =>
[table_aliases:protected] => Array
(
)
[clauses:protected] => Array
(
)
[has_or_relation:protected] =>
)
[date_query] =>
[request] => SELECT SQL_CALC_FOUND_ROWS wp_posts.ID
FROM wp_posts
WHERE 1=1 AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
ORDER BY RAND()
LIMIT 0, 3
[posts] => Array
(
[0] => WP_Post Object
(
[ID] => 5031
[post_author] => 3
[post_date] => 2026-08-10 12:17:19
[post_date_gmt] => 2026-08-10 16:17:19
[post_content] =>
Attention Stony Brook University Faculy and Staff: Applications for the second cycle of the President’s Fast Impact Fund (FIF) opened August 3, 2026. Open to all Stony Brook faculty and staff, this special initiative supports immediate-impact projects that can be launched quickly and deliver results within six to ten months.
The FIF provides awards of up to $300,000 focused on low‑investment, high‑reward initiatives that create visible, positive change. Examples of projects that would be considered include specialized equipment or technology acquisitions, pilot programs or proof‑of‑concept initiatives, targeted renovations or seed funding, among other opportunities.
All proposals must include a customized, high-level budget and be endorsed by the relevant vice president or dean with authority to implement the project. Applications for the August cycle will be available beginning August 3 with submissions due Friday, August 21 by 5 pm, ET. Please visit the Fast Impact Fund website for additional information and to submit an application.
[post_title] => SBU President’s Fast Impact Fund (FIF)
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => sbu-presidents-fast-impact-fund-fif
[to_ping] =>
[pinged] =>
[post_modified] => 2026-08-19 08:30:44
[post_modified_gmt] => 2026-08-19 12:30:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=5031
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 3658
[post_author] => 3
[post_date] => 2021-03-22 14:57:42
[post_date_gmt] => 2021-03-22 14:57:42
[post_content] =>
Tools that accelerate medical countermeasure screening and development are vital to improving human health – from enabling personalized medicine to responding to health security threats such as pandemics. To this end, BARDA, in partnership with the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health, has launched the new ImmuneChip+ program.
We aim to partner with innovators to support the development of advanced microphysiological systems / tissue chip platforms that integrate a component of the human immune system. The objective of the program is to develop a set of set of mature ImmuneChips, combining a previously validated model of a vital human tissue (e.g. lung, heart, kidney) with an immune system component, in a single platform that can be machine-manufactured and that includes multiple in-line sensors for long-term tissue monitoring. With this program, we aim to further enhance the usability of tissue chips and position them as useful tools in the drug development process and for personalized therapeutics.
For more details, please visit BARDA DRIVe program at https://drive.hhs.gov/immunechip.html
[post_title] => BARDA: Immunechip+ Program Overview
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => barda-immunechip-program-overview
[to_ping] =>
[pinged] =>
[post_modified] => 2021-03-22 15:01:19
[post_modified_gmt] => 2021-03-22 15:01:19
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=3658
[menu_order] => 53
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 2253
[post_author] => 3
[post_date] => 2016-06-16 16:15:26
[post_date_gmt] => 2016-06-16 16:15:26
[post_content] => 
Rgenix, a cancer therapeutics company developing first-in-class drugs targeting novel cancer pathways, announced a $33 million Series B financing led by Novo A/S and Sofinnova Partners, with participation from existing investors including Partnership Fund for New York City, Alexandria Venture Investments, and Conegliano Ventures LP. The financing will support clinical development of Rgenix’s lead drug candidates, RGX-104 and RGX-202, as well as further development of its therapeutics pipeline.
In connection with the financing, Nilesh Kumar of Novo Ventures and Antoine Papiernik of Sofinnova Partners will join the Rgenix Board of Directors together with existing members, including Executive Chairman Eric Rowinsky, M.D., Masoud Tavazoie, M.D. Ph.D., Nancy Chang, Ph.D., and Saeed Tavazoie, Ph.D. Read the full press release about Rgenix’s financing here.
[post_title] => Rgenix Announces $33M Series B Financing
[post_excerpt] => Rgenix, a cancer therapeutics company developing first-in-class drugs targeting novel cancer pathways, announced a $33 million Series B financing led by Novo A/S and Sofinnova Partners, with participation from existing investors including Partnership Fund for New York City, Alexandria Venture Investments, and Conegliano Ventures LP. The financing will support clinical development of Rgenix’s lead drug candidates, RGX-104 and RGX-202, as well as further development of its therapeutics pipeline.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => rgenix-announces-33m-series-b-financing
[to_ping] =>
[pinged] =>
[post_modified] => 2016-06-16 16:17:16
[post_modified_gmt] => 2016-06-16 16:17:16
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/?p=2253
[menu_order] => 176
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 3750
[post_author] => 4
[post_date] => 2021-04-07 19:20:10
[post_date_gmt] => 2021-04-07 19:20:10
[post_content] =>
To accelerate the development of the next generation of masks, BARDA and NIOSH have partnered to launch the Mask Innovation Challenge: Building Tomorrow’s Mask. The Mask Innovation Challenge aims to improve the comfort, utility, and protective capabilities of available community masks that are worn during day-to-day activities when physical distancing is not possible. This competition is designed to support the development of mask designs that meet predefined performance standards, while providing increased comfort and durability to the average consumer.
Can you help build a better mask – one that people are interested in wearing? You will have helped solved one of the biggest problems of the day! The mask design innovation challenge puts up a $500,000 prize purse for new mask designs that overcome the common reasons people don’t wear masks in the current pandemic. Phase 1 is design, due 5 p.m. April 21, 2021; phase 2 is testing of prototypes by NIOSH scientists and partner labs. Learn more at drive.hhs.gov/mask_challenge.html and then see Challenge.gov for the rules, criteria, timelines and how to submit.
Mask Innovation Challenge Event 4/15
Don't miss the Mask Innovation Challenge event at the Venture Café at UCSC on Thursday, April 15, 2021: "Why we need to innovate on the non-medical grade face mask" from 3-4pm EDT. HHS’s Biomedical Advanced Research and Development Authority (BARDA) will discuss comfort, utility, and protective factor of current non-medical grade face masks as well as opportunities to innovate on these designs.
Event link*: https://venturecafephiladelphia.org/event/why-we-need-to-innovate-on-the-non-medical-grade-face-mask/
8this link can be used to access the event on the day of the talk, no registration required)
[post_title] => BARDA: Mask Innovation Challenge
[post_excerpt] => Can you help build a better mask – one that people are interested in wearing? The mask design innovation challenge puts up a $500,000 prize purse for new mask designs that overcome the common reasons people don’t wear masks in the current pandemic.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => barda-mask-innovation-challenge
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-20 16:13:51
[post_modified_gmt] => 2021-09-20 16:13:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=3750
[menu_order] => 48
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 4
[current_post] => -1
[before_loop] => 1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 5031
[post_author] => 3
[post_date] => 2026-08-10 12:17:19
[post_date_gmt] => 2026-08-10 16:17:19
[post_content] =>
Attention Stony Brook University Faculy and Staff: Applications for the second cycle of the President’s Fast Impact Fund (FIF) opened August 3, 2026. Open to all Stony Brook faculty and staff, this special initiative supports immediate-impact projects that can be launched quickly and deliver results within six to ten months.
The FIF provides awards of up to $300,000 focused on low‑investment, high‑reward initiatives that create visible, positive change. Examples of projects that would be considered include specialized equipment or technology acquisitions, pilot programs or proof‑of‑concept initiatives, targeted renovations or seed funding, among other opportunities.
All proposals must include a customized, high-level budget and be endorsed by the relevant vice president or dean with authority to implement the project. Applications for the August cycle will be available beginning August 3 with submissions due Friday, August 21 by 5 pm, ET. Please visit the Fast Impact Fund website for additional information and to submit an application.
[post_title] => SBU President’s Fast Impact Fund (FIF)
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => sbu-presidents-fast-impact-fund-fif
[to_ping] =>
[pinged] =>
[post_modified] => 2026-08-19 08:30:44
[post_modified_gmt] => 2026-08-19 12:30:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=5031
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[comment_count] => 0
[current_comment] => -1
[found_posts] => 284
[max_num_pages] => 95
[max_num_comment_pages] => 0
[is_single] =>
[is_preview] =>
[is_page] =>
[is_archive] =>
[is_date] =>
[is_year] =>
[is_month] =>
[is_day] =>
[is_time] =>
[is_author] =>
[is_category] =>
[is_tag] =>
[is_tax] =>
[is_search] =>
[is_feed] =>
[is_comment_feed] =>
[is_trackback] =>
[is_home] => 1
[is_privacy_policy] =>
[is_404] =>
[is_embed] =>
[is_paged] =>
[is_admin] =>
[is_attachment] =>
[is_singular] =>
[is_robots] =>
[is_favicon] =>
[is_posts_page] =>
[is_post_type_archive] =>
[query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0
[query_vars_changed:WP_Query:private] =>
[thumbnails_cached] =>
[allow_query_attachment_by_filename:protected] =>
[stopwords:WP_Query:private] =>
[compat_fields:WP_Query:private] => Array
(
[0] => query_vars_hash
[1] => query_vars_changed
)
[compat_methods:WP_Query:private] => Array
(
[0] => init_query_flags
[1] => parse_tax_query
)
[query_cache_key:WP_Query:private] =>
)
